Estrogen Management & Aromatase Inhibitors: The Complete Guide

Overview

Aromatase inhibitors are a class of drugs that block the aromatase enzyme (CYP19A1), which converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone). Originally developed for estrogen-receptor-positive breast cancer in postmenopausal women, AIs have been adopted off-label in men's health — primarily as adjuncts to testosterone replacement therapy (TRT) to manage elevated estradiol levels.

The most commonly used AI in the TRT context is anastrozole (brand name: Arimidex). Other AIs include letrozole (Femara) and exemestane (Aromasin), though anastrozole is by far the most frequently prescribed for male estrogen management.

In men receiving exogenous testosterone, the aromatase enzyme converts a portion of that testosterone into estradiol (E2). Some degree of aromatization is normal and physiologically necessary. However, in certain individuals — particularly those with higher body fat, higher testosterone doses, or genetic variation in aromatase activity — estradiol can rise to levels that produce symptoms such as gynecomastia (breast tissue development), water retention, mood disturbance, and sexual dysfunction (Burnett-Bowie et al., 2009).

The central challenge in estrogen management during TRT is balance. Landmark research by Finkelstein et al. demonstrated that estrogen is not merely a "female hormone" — it plays critical roles in male bone health, fat metabolism, and sexual function. Suppressing estrogen too aggressively with AIs can cause joint pain, bone density loss, adverse lipid changes, cognitive effects, and sexual dysfunction — the very symptoms many men are trying to avoid (Finkelstein et al., 2013).

Quick Facts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

How It Works

The Aromatase Enzyme

Aromatase (cytochrome P450 19A1, or CYP19A1) is the enzyme responsible for the final step in estrogen biosynthesis — the conversion of androgens to estrogens. Specifically:

• Testosterone → Estradiol (E2) — the most biologically active estrogen
• Androstenedione → Estrone (E1) — a weaker estrogen

Aromatase is expressed in multiple tissues: adipose (fat) tissue, brain, bone, liver, skin, gonads, and blood vessels. In men, adipose tissue is the primary site of peripheral aromatization. This is why men with higher body fat percentages tend to have higher baseline estradiol levels and may experience greater estradiol elevation on TRT (Cohen et al., 1999).

Types of Aromatase Inhibitors

Why Anastrozole Is Preferred in TRT

Anastrozole is the most commonly used AI in male TRT for several reasons:

• Moderate potency: Anastrozole reduces estradiol by approximately 50–70% at typical doses, allowing for dose titration to target a range rather than near-complete suppression
• Reversibility: If estrogen drops too low, stopping anastrozole allows estradiol to recover within days
• Long half-life (~46.8 hours): Allows convenient dosing schedules (1–3× per week)
• Extensive clinical experience: Decades of use in breast cancer provides a well-characterized side effect profile
• Low cost: Generic anastrozole is widely available at $10–$30/month

Letrozole is more potent than anastrozole and carries a higher risk of over-suppression of estrogen. It is occasionally used in male infertility protocols but is generally considered too aggressive for routine TRT estrogen management. Exemestane's irreversible mechanism makes dose adjustment less predictable (Loves et al., 2008).

Estrogen's Role in Men

Understanding why estrogen management requires careful balance requires understanding what estrogen does in men. The Finkelstein et al. study — a landmark controlled trial — demonstrated that estrogen deficiency in men produces specific, measurable consequences (Finkelstein et al., 2013):

• Bone health: Estrogen is the primary hormone responsible for bone mineral density maintenance in men — more important than testosterone for this function. Estrogen deficiency leads to accelerated bone loss and increased fracture risk.
• Fat metabolism: Estrogen helps regulate fat distribution. Men with suppressed estrogen accumulate more abdominal and subcutaneous fat.
• Sexual function: Both testosterone and estrogen contribute to male libido and erectile function. Estrogen deficiency (not just testosterone deficiency) impairs sexual desire.
• Cardiovascular protection: Estrogen has vasodilatory and cardioprotective effects. Suppressed estrogen is associated with adverse lipid profiles (increased LDL, decreased HDL).
• Cognitive function: Estrogen receptors are abundant in the male brain, and estrogen plays roles in neuroprotection and cognitive processing.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Research

Finkelstein et al. (2013) — The Landmark Estrogen Study

This New England Journal of Medicine study is arguably the most important paper on estrogen's role in men. Finkelstein and colleagues administered a GnRH agonist (to suppress endogenous testosterone and estrogen) to 400 healthy men aged 20–50, then provided graded doses of testosterone with or without an aromatase inhibitor (anastrozole) to separate the effects of testosterone from estrogen (Finkelstein et al., 2013).

Key findings:

• Fat accumulation increased significantly when estrogen was suppressed — even when testosterone levels were maintained at normal or above-normal levels. This demonstrated that estrogen, not testosterone, is the primary regulator of fat metabolism in men.
• Sexual function declined when estrogen was suppressed below normal levels, independent of testosterone status. Libido and erectile function required adequate estrogen.
• Lean mass and strength were primarily testosterone-dependent, with less contribution from estrogen.
• The threshold effect: The most significant deterioration occurred when estradiol dropped below approximately 10 pg/mL — indicating that very low estrogen is harmful in men.

Burnett-Bowie et al. (2009) — AI Effects on Male Bone

This study examined the effects of anastrozole on bone mineral density (BMD) and bone turnover markers in older men. The researchers found that anastrozole significantly increased bone resorption markers and decreased BMD at multiple skeletal sites over 12 months (Burnett-Bowie et al., 2009).

Key findings:

• Anastrozole increased N-telopeptide (a bone resorption marker) by approximately 25–30%
• BMD decreased at the spine and hip — sites most vulnerable to osteoporotic fracture
• The bone effects were seen even with relatively modest estradiol reduction
• The study reinforced that estrogen is the dominant hormonal regulator of bone metabolism in men — a finding consistent with the clinical observation that men with aromatase deficiency or estrogen receptor mutations develop severe osteoporosis

Loves et al. (2008) — Letrozole in Obese Men

Loves and colleagues studied the effects of letrozole (a more potent AI than anastrozole) in obese men with hypogonadism and elevated estradiol. The study demonstrated that AI therapy effectively normalized the testosterone-to-estradiol ratio, but raised concerns about the metabolic consequences of aggressive estrogen suppression (Loves et al., 2008).

Key findings:

• Letrozole 2.5 mg/week normalized testosterone levels in obese hypogonadal men
• Estradiol was substantially reduced — in some cases below the physiological range
• The study highlighted the risk of over-suppression with potent AIs, particularly in patients where the goal is hormonal balance rather than maximal estrogen reduction
• Adverse lipid changes were observed with estrogen suppression

Additional Key Research

• Carani et al. (1997): Case report of a man with aromatase deficiency (congenital inability to produce estrogen) who developed severe osteoporosis, unfused epiphyses, and metabolic abnormalities — directly demonstrating that men require estrogen for normal skeletal development and maintenance (Carani et al., 1997).
• T'Sjoen et al. (2005): Demonstrated that estradiol levels correlate with bone mineral density in healthy men, independent of testosterone levels, confirming estrogen's dominant role in male bone metabolism (T'Sjoen et al., 2005).
• de Ronde et al. (2009): Reviewed the role of estrogens in male physiology, concluding that estrogen is an essential hormone for men with important effects on bone, brain, cardiovascular system, and sexual function (de Ronde & de Jong, 2011).

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Uses

FDA-Approved Indication

Breast cancer: Anastrozole is FDA-approved as adjuvant treatment for hormone-receptor-positive early breast cancer in postmenopausal women, and as first-line treatment for advanced breast cancer in postmenopausal women. This is its primary approved use and the context in which most safety data has been generated.

Off-Label Uses in Men

When Is an AI Actually Needed During TRT?

The question of when to prescribe an AI is clinically important because over-prescribing is common (see Over-Prescribing tab). Evidence-based indications for AI use during TRT include:

• Symptomatic estradiol elevation — documented elevated E2 (typically >50–60 pg/mL, though individual thresholds vary) accompanied by clinical symptoms: gynecomastia, significant water retention, or estrogen-related mood/sexual dysfunction
• Gynecomastia — palpable breast tissue development during TRT
• Failure of dose adjustment — when lowering the testosterone dose or increasing injection frequency does not adequately control estradiol

AIs are generally not indicated for:

• Mildly elevated E2 without symptoms
• Routine "prophylactic" use with all TRT prescriptions
• Targeting an arbitrary E2 number (e.g., "keep E2 under 30 pg/mL") without clinical correlation

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Dosing

Commonly Reported Protocols (Anastrozole)

Dosing protocols above reflect reported clinical practice patterns for off-label use of anastrozole in male TRT. These are not FDA-approved dosing guidelines for this indication. References: Burnett-Bowie et al., 2009 · Loves et al., 2008 · Finkelstein et al., 2013

Dose Titration Approach

Best practice involves a "start low, titrate up" approach:

1. Baseline labs: Measure estradiol (sensitive assay / LC-MS/MS preferred), total testosterone, free testosterone, SHBG, and CBC before starting an AI
2. Start low: Begin with the lowest effective dose (0.25 mg 1–2× per week)
3. Follow-up labs: Recheck estradiol and testosterone 4–6 weeks after starting or adjusting the AI dose
4. Clinical correlation: Adjust based on both lab values AND symptoms — do not chase a specific number
5. Reassess need: Periodically evaluate whether the AI is still necessary, particularly after weight loss, testosterone dose reduction, or increased injection frequency

Target Estradiol Range

There is no universally agreed-upon "target" estradiol level for men on TRT. Published reference ranges and clinical approaches vary:

Sources: Finkelstein et al., 2013 — Gonadal steroids and body composition in men (NEJM) · Krzastek et al., 2021 — Impact of aromatase inhibitor therapy on estradiol levels in men on TRT · Khodamoradi et al., 2024 — Testosterone:estradiol ratio review

Important Considerations

• Assay matters: The standard immunoassay for estradiol can be inaccurate at the lower levels seen in men. The LC-MS/MS (liquid chromatography–tandem mass spectrometry) method — sometimes called the "sensitive" or "ultrasensitive" estradiol assay — is more accurate and should be used for male estradiol monitoring when available.
• Timing of labs: Draw blood at trough (just before the next testosterone injection) for consistent results. Estradiol fluctuates with testosterone levels.
• Injection frequency reduces E2: Splitting testosterone doses into more frequent injections (e.g., every-other-day or daily subcutaneous) produces more stable testosterone levels and typically results in lower estradiol peaks — sometimes eliminating the need for an AI entirely.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Side Effects

Common Side Effects

Bone Health: The Critical Risk

The bone health implications of AI use in men deserve particular attention. Research demonstrates that estrogen — not testosterone — is the dominant hormone regulating bone mineral density in men. The Burnett-Bowie et al. study showed that anastrozole increased bone resorption markers by 25–30% and decreased BMD at the spine and hip within 12 months (Burnett-Bowie et al., 2009).

Men using AIs chronically should consider:

• Baseline DEXA scan before or shortly after starting AI therapy
• Follow-up DEXA scans at 1–2 year intervals
• Adequate calcium intake (1,000–1,200 mg/day from diet and/or supplements)
• Vitamin D optimization (target 25-OH vitamin D of 40–60 ng/mL)
• Weight-bearing exercise for bone maintenance
• Reassessment of whether AI therapy is still necessary

Signs of Estrogen Over-Suppression (Low E2)

Recognizing the symptoms of low estrogen in men is critical for appropriate AI management:

• Joint pain, stiffness, and cracking — particularly in the hands, knees, and elbows
• Dry, thin skin
• Fatigue and low energy
• Decreased libido (despite adequate testosterone)
• Erectile dysfunction
• Depression or flat mood
• Increased urinary frequency
• Bone pain

If these symptoms develop while taking an AI, the appropriate response is typically to reduce the AI dose or discontinue it and recheck estradiol levels — not to increase testosterone.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Women & Estrogen

Estrogen Replacement in Women

Estrogen is the primary female sex hormone, essential for reproductive function, bone health, cardiovascular protection, cognitive function, skin integrity, and overall well-being. During perimenopause and menopause, estrogen production declines significantly, producing symptoms that can substantially impact quality of life:

• Hot flashes and night sweats
• Vaginal dryness and atrophy
• Sleep disturbance
• Mood changes, anxiety, depression
• Bone density loss (accelerated osteoporosis risk)
• Cognitive changes
• Skin thinning and reduced elasticity

Hormone Replacement Therapy (HRT)

Menopausal hormone therapy (MHT), also called hormone replacement therapy (HRT), involves estrogen supplementation — sometimes combined with progesterone — to replace declining ovarian estrogen production. Common formulations include:

AIs in Women: Breast Cancer Context

In women, aromatase inhibitors are used in an entirely different context than in men — as treatment for estrogen-receptor-positive (ER+) breast cancer. In postmenopausal women with ER+ breast cancer, AIs (anastrozole, letrozole, exemestane) are standard adjuvant therapy, typically prescribed for 5–10 years. The goal is maximal estrogen suppression to prevent cancer recurrence — fundamentally different from the balanced approach sought in male TRT.

Side effects of AIs in women mirror those in men but are often more pronounced due to the near-complete estrogen suppression achieved at oncologic doses: joint pain, bone loss, hot flashes, mood changes, vaginal dryness, and cardiovascular risk changes.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Cost

Typical Pricing

Insurance Coverage

Insurance coverage for anastrozole depends on the indication:

• Breast cancer (FDA-approved): Typically covered with standard copay
• Off-label TRT use: Coverage varies. Some insurers cover off-label prescriptions; others deny claims for non-approved indications. Prior authorization may be required. Many patients pay out-of-pocket or use discount programs.
• Male infertility: Coverage depends on the insurer and state mandates for fertility treatment coverage

Cost Comparison with Other TRT Adjuncts

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

The Over-Prescribing Problem

How Over-Prescribing Happens

Several factors contribute to the widespread over-prescribing of AIs in male TRT:

• Arbitrary E2 targets: Many TRT clinics set fixed estradiol targets (e.g., "keep E2 under 30 pg/mL" or "maintain E2 at 20–25 pg/mL") without evidence supporting these specific numbers. These targets often lead to unnecessary AI use and estrogen over-suppression.
• Prophylactic prescribing: Some providers prescribe an AI to every patient starting TRT — before estradiol has been measured or symptoms have developed. This "just in case" approach exposes patients to AI side effects without established benefit.
• Misattribution of symptoms: Water retention, mood changes, and libido fluctuations that occur during TRT initiation are frequently attributed to "high estrogen" and treated with AIs, even when estradiol levels are within normal range. These symptoms often resolve on their own as the body adjusts to stable testosterone levels.
• Bodybuilding-derived protocols: TRT protocols at some clinics are influenced by bodybuilding and anabolic steroid use patterns, where supraphysiologic testosterone doses produce genuinely excessive estradiol levels. These protocols are inappropriate for standard TRT doses.
• Fear of gynecomastia: While gynecomastia is a legitimate concern, its incidence on standard TRT doses is relatively low. Prophylactic AI use to prevent a low-probability outcome exposes all patients to guaranteed AI side effects.

What the Evidence Shows

The research is consistent on several key points:

• Most men on TRT do not develop problematic estradiol elevations. At standard replacement doses (100–200 mg/week testosterone cypionate or equivalent), most men achieve estradiol levels within or modestly above the reference range without intervention.
• Estrogen is protective, not harmful. The Finkelstein et al. data clearly demonstrates that estrogen deficiency — not estrogen excess — produces the most clinically significant negative outcomes in men (Finkelstein et al., 2013).
• Dose adjustment is first-line. Reducing the testosterone dose or increasing injection frequency (to reduce peak-trough variation) is the preferred approach to managing elevated E2 before adding an AI.
• AI side effects are real and significant. Joint pain, bone density loss, lipid changes, and sexual dysfunction from estrogen over-suppression can be worse than the symptoms the AI is prescribed to prevent.

Alternatives to AI Use

Before prescribing an AI, providers should consider:

• Reduce testosterone dose: Less substrate for aromatization = less estradiol production
• Increase injection frequency: Splitting weekly doses into 2–3 smaller injections reduces estradiol peaks. Some patients do well with daily subcutaneous micro-doses.
• Weight loss: Adipose tissue is the primary site of peripheral aromatization. Reducing body fat directly reduces aromatase activity and E2 production.
• Switch testosterone formulation: Some formulations (e.g., testosterone cream/gel) may produce different estradiol levels than injectable testosterone due to differences in absorption kinetics.
• Wait and reassess: E2 levels often stabilize within the first 6–8 weeks of TRT as the body reaches steady state. Early elevation may resolve without intervention.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Questions & Answers

Question: Do all men on TRT need an aromatase inhibitor?

Answer: No. Most men on standard-dose TRT (100–200 mg/week testosterone) do not need an AI. AIs should be reserved for men with documented elevated estradiol AND accompanying symptoms (gynecomastia, significant water retention, estrogen-related sexual dysfunction). The Finkelstein et al. study demonstrated that men need adequate estrogen for bone health, fat metabolism, and sexual function — routine suppression is counterproductive (Finkelstein et al., 2013).

Question: What estradiol level is "too high" for men on TRT?

Answer: There is no universally agreed-upon upper limit. The standard male reference range is approximately 10–40 pg/mL, but men on TRT commonly have higher levels (40–60+ pg/mL) without symptoms or clinical problems. Current evidence supports a symptom-based approach rather than treating to a specific number. An estradiol of 55 pg/mL in an asymptomatic man generally does not require treatment. An estradiol of 35 pg/mL in a man with breast tenderness and significant edema may warrant intervention. Context and clinical correlation are essential.

Question: Can low estrogen in men cause the same symptoms as high estrogen?

Answer: Yes — and this is a critical point. Many symptoms attributed to "high estrogen" (water retention, mood changes, decreased libido, erectile dysfunction) can also be caused by low estrogen from AI over-suppression. The Finkelstein et al. data showed that men with suppressed estrogen experienced decreased libido and sexual function, increased fat accumulation, and mood changes — symptoms nearly identical to those often blamed on high estrogen (Finkelstein et al., 2013). This overlap makes it essential to check labs rather than assume the cause of symptoms.

Question: Is anastrozole safe for long-term use in men?

Answer: Long-term safety data for anastrozole in men is limited. The breast cancer literature (in women) documents significant bone density loss, joint problems, and cardiovascular risk changes with chronic use. The Burnett-Bowie et al. study demonstrated measurable bone loss in men within 12 months of anastrozole use (Burnett-Bowie et al., 2009). Men using AIs chronically should monitor bone density (DEXA scans), lipid panels, and joint symptoms. Periodic reassessment of whether the AI is still necessary is important.

Question: Can I use an AI instead of TRT to raise my testosterone?

Answer: AI monotherapy (anastrozole or letrozole without exogenous testosterone) has been studied as an alternative to TRT. By blocking estrogen's negative feedback on the hypothalamus, AIs can increase LH and FSH secretion, which stimulates endogenous testosterone production. This approach preserves fertility (unlike exogenous testosterone, which suppresses spermatogenesis). However, AI monotherapy has limitations: testosterone increases are typically modest compared to TRT, the approach requires functional testes, and estrogen suppression carries the same side effect risks discussed throughout this article. It is not FDA-approved for this indication (Loves et al., 2008).

Question: What is the difference between an AI and a SERM?

Answer: Aromatase inhibitors (AIs) reduce estrogen production by blocking the aromatase enzyme — they lower circulating estradiol levels throughout the body. Selective estrogen receptor modulators (SERMs), such as tamoxifen and clomiphene, do not reduce estrogen production — instead, they block estrogen receptors in specific tissues (like breast tissue) while activating them in others (like bone). SERMs preserve bone-protective estrogen effects while blocking estrogen at the breast. For gynecomastia specifically, SERMs (tamoxifen, raloxifene) are often preferred over AIs because they address the breast tissue directly without causing systemic estrogen depletion.

Question: Does body fat affect how much I aromatize?

Answer: Yes. Adipose (fat) tissue is the primary site of peripheral aromatase expression in men. Men with higher body fat percentages have more aromatase enzyme activity and convert more testosterone to estradiol. This is why obese men tend to have higher baseline estradiol levels and may experience greater estradiol elevation on TRT. Weight loss is one of the most effective non-pharmacologic strategies for reducing aromatization and lowering estradiol.

Question: Should I take an AI on injection days or on specific days?

Answer: There is no strong evidence favoring one timing protocol over another. Some providers recommend taking the AI on injection days (to coincide with peak testosterone and thus peak aromatization), while others prefer non-injection days or evenly spaced dosing. Given anastrozole's long half-life (~46.8 hours), the timing within a week is less critical than the total weekly dose. Consistency in timing is more important than the specific day chosen.

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.

Key Takeaways

Based on the available evidence:

• Aromatase inhibitors block the conversion of testosterone to estradiol. Anastrozole is the most commonly used AI in male TRT, dosed at 0.25–1 mg, 1–3× per week. Generic anastrozole costs approximately $10–$30/month.
• Estrogen is essential for male health. The Finkelstein et al. (2013) study demonstrated that estrogen — not just testosterone — is required for bone health, fat metabolism, and sexual function in men. Suppressing estrogen too aggressively causes measurable harm.
• AIs are over-prescribed in men's TRT. Many clinics routinely prescribe AIs to all TRT patients or target arbitrarily low estradiol levels. Most men on standard TRT doses do not need an AI. Dose adjustment and increased injection frequency should be tried first.
• Joint pain and bone loss are the primary risks of AI use in men. The Burnett-Bowie et al. (2009) study documented significant bone resorption and BMD loss within 12 months of anastrozole use. Chronic AI users should monitor bone density.
• Low estrogen symptoms mimic high estrogen symptoms. Decreased libido, mood changes, water retention, and erectile dysfunction can result from either high or low estradiol — making lab monitoring essential rather than treating symptoms alone.
• Treat symptoms, not numbers. An asymptomatic man with estradiol of 50–60 pg/mL on TRT generally does not need an AI. A symptom-based approach, using the sensitive (LC-MS/MS) estradiol assay, is preferred over chasing arbitrary targets.
• In women, AIs serve a completely different purpose — treatment of estrogen-receptor-positive breast cancer. Women approaching menopause typically need estrogen replacement (HRT), not estrogen suppression.

Questions to Ask a Provider

• Do my estradiol levels and symptoms actually warrant an AI, or can we adjust my testosterone dose or injection frequency first?
• What specific estradiol level are you targeting, and what is the evidence behind that target?
• Are you using the sensitive (LC-MS/MS) estradiol assay for my bloodwork?
• What are the risks of AI use at this dose, particularly for my bones and joints?
• How often should I have follow-up labs to monitor estradiol levels?
• Should I get a baseline DEXA scan before starting or continuing an AI?
• Is there a plan to taper or discontinue the AI if my symptoms resolve or if I lose weight?

Sources & Further Reading

Landmark Studies

• Finkelstein JS, Lee H, Burnett-Bowie SA, et al. — "Gonadal steroids and body composition, strength, and sexual function in men" — New England Journal of Medicine (2013)
• Burnett-Bowie SA, McKay EA, Lee H, Leder BZ — "Effects of aromatase inhibition on bone mineral density and bone turnover in older men with low testosterone levels" — Journal of Clinical Endocrinology & Metabolism (2009)
• Loves S, Ruinemans-Koerts J, de Boer H — "Letrozole once a week normalizes serum testosterone in obesity-related male hypogonadism" — European Journal of Endocrinology (2008)

Estrogen in Male Physiology

• Carani C, Qin K, Simoni M, et al. — "Effect of testosterone and estradiol in a man with aromatase deficiency" — Journal of Clinical Endocrinology & Metabolism (1997)
• T'Sjoen GG, Kaufman JM, Goemaere S — "Bone mineral density and body composition in male-to-female transsexual persons" — Archives of Sexual Behavior (2005)
• de Ronde W, de Jong FH — "Aromatase inhibitors in men: effects and therapeutic options" — Reproductive Biology and Endocrinology (2011)

Aromatase Inhibitor Pharmacology

• Loves et al. (2008) — Letrozole pharmacology and efficacy in men
• Burnett-Bowie et al. (2009) — Anastrozole bone and metabolic effects

Clinical Practice & Guidelines

• Bhasin S, Brito JP, Cunningham GR, et al. — "Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline" — Journal of Clinical Endocrinology & Metabolism (2018)

Women's Estrogen Replacement

• The NAMS 2017 Hormone Therapy Position Statement Advisory Panel — "The 2017 hormone therapy position statement of The North American Menopause Society" — Menopause (2017)

This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider.